DAEWOONG CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18,820 KRW | +0.64% |
|
+3.75% | -8.86% |
| Apr. 24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| Mar. 08 | Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
ETFs positioned on Daewoong Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | -0.10% | - |
Daewoong Co Ltd is a Korea-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
18,820
KRW
Average target price
25,000
KRW
Spread / Average Target
+32.84%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.86% | 556M | |
| +19.27% | 43.75B | |
| +27.47% | 22.06B | |
| +15.11% | 14.46B | |
| +12.33% | 13.62B | |
| +38.36% | 11.61B | |
| -9.54% | 6.9B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.32B |
- Stock Market
- Equities
- A003090 Stock
- Funds and ETFs Daewoong Co., Ltd.
